Inflammation in Atherosclerosis : Transition From Theory to Practice
スポンサーリンク
概要
- 論文の詳細を見る
Inflammation drives the formation, progression, and rupture of atherosclerotic plaques. Experimental studies have demonstrated that an inflammatory subset of monocytes/macrophages preferentially accumulate in atherosclerotic plaque and produce proinflammatory cytokines. T lymphocytes can contribute to inflammatory processes that promote thrombosis by stimulating production of collagen-degrading proteinases and the potent procoagulant tissue factor. Recent data link obesity, inflammation, and modifiers of atherosclerotic events, a nexus of growing clinical concern given the worldwide increase in the prevalence of obesity. Modulators of inflammation derived from visceral adipose tissue evoke production of acute phase reactants in the liver, implicated in thrombogenesis and clot stability. Additionally, C-reactive protein levels rise with increasing levels of visceral adipose tissue. Adipose tissue in obese mice contains increased numbers of macrophages and T lymphocytes, increased T lymphocyte activation, and increased interferon-γ (IFN-γ) expression. IFN-γ deficiency in mice reduces production of inflammatory cytokines and inflammatory cell accumulation in adipose tissue. Another series of in vitro and in vivo mouse experiments affirmed that adiponectin, an adipocytokine, the plasma levels of which drop with obesity, acts as an endogenous antiinflammatory modulator of both innate and adaptive immunity in atherogenesis. Thus, accumulating experimental evidence supports a key role for inflammation as a link between risk factors for atherosclerosis and the biology that underlies the complications of this disease. The recent JUPITER trial supports the clinical utility of an assessment of inflammatory status in guiding intervention to limit cardiovascular events. Inflammation is thus moving from a theoretical concept to a tool that provides practical clinical utility in risk assessment and targeting of therapy. (Circ J 2010; 74: 213-220)
- 2010-01-25
著者
-
LIBBY Peter
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School
-
OKAMOTO Yoshihisa
Department of Bioregulation, Nippon Medical School
-
ROCHA Viviane
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School
-
FOLCO Eduardo
Division of Cardiovascular Medicine, Brigham and Women's Hospital, Harvard Medical School
-
Libby Peter
Division Of Cardiovascular Medicine Brigham And Women's Hospital Harvard Medical School
-
Rocha Viviane
Division Of Cardiovascular Medicine Brigham And Women's Hospital Harvard Medical School
-
Folco Eduardo
Division Of Cardiovascular Medicine Brigham And Women's Hospital Harvard Medical School
-
Okamoto Yoshihisa
Department Of Bioregulation Nippon Medical School
関連論文
- Inflammation in Atherosclerosis : Transition From Theory to Practice
- Reciprocal Relationship between Adiponectin and C-Reactive Protein
- Contribution of Adiponectin Gene Mutation to Coronary Artery Disease
- Adiponectin Dysregulation as a Common Cause of Insulin Resistance and Atherosclerosis
- Role of Adiponectin in Preventing Vascular Stenosis : The Missing Link of Adipo-Vascular Axis
- Clinical Significance of High-Molecular Weight Form of Adiponectin in Male Patients With Coronary Artery Disease
- Late Postprandial Hypoglycemia due to Bioactive Insulin Dissociation from Autoantibody Leading to Unconsciousness in a Patient with Insulin Autoimmune Syndrome
- Association of Hypo-Adiponectinemia with Coronary Artery Disease in Women
- A Novel Plasma Protein Abundantly Expressed in Visceral Fat, Visfatin, Associated with Coronary Artery Disease
- A Plasma Protein Abundantly Expressed in Visceral Fat, Visfatin Modulates Inflammatory Response in Human Monocyte-derived Macrophages
- Adipocyte-Derived Plasma Protein, Adiponectin, Prevents Atherosclerosis in Apolipoprotein E-Deficient Mice
- A Plasma Protein Abundantly Expressed in Visceral Fat, Visfatin, Increases Endothelial MCP-1 Expression and Contributes to Coronary Artery Disease
- Conversion of Brain-Specific Complex Type Sugar Chains by N-Acetyl-β-_D-Hexosaminidase B
- Conversion of Brain-Specific Complex Type Sugar Chains by N-Acetyl-.BETA.-D-Hexosaminidase B.